OCGN Stock Forecast: Covaxin’s FDA Status Marks the Future
This OCGN stock forecast article was written by Maria Grishaev, Analyst at I Know First.
Executive Summary
- Ocugen had a good year in 2020. The stock price went up by 239.52% despite the COVID-19 pandemic.
- A deal to commercialize Covaxin in the U.S. was signed with Bharat Biotech can have an impact on revenue if the FDA will give the vaccine an Emergency Use Authorization.
- Quantitative analysis results indicate bullish signals after stock price topped out the moving average line.
- OCGN deserves a one-year target price of $13, representing potential revenue growth.
Read The Full Premium Article
This Ocugen stock prediction article was written by Viktoriya Voronchuk – Financial Analyst intern 
Read The FullPremium Article
